GPX4-IN-23 

GPX4-IN-23 (Compound 3e) is a GPX4 inhibitor with an IC₅₀ of 0.27 μM. GPX4-IN-23 induces Ferroptosis by enhancing lipid peroxidation, ROS production, and intracellular GSH depletion. GPX4-IN-23 exhibits antiproliferative activity against central nervous system cancer cells. GPX4-IN-23 can be used in studies related to central nervous system cancers^[1].

GPX4-IN-23 potently inhibits recombinant GPX4 enzyme, with an IC₅₀ of 0.27 μM^[1].
GPX4-IN-23 (48 h) potently inhibits the proliferation of SNB-75 central nervous system cancer cells, with an IC₅₀ of 3.22 μM^[1].
GPX4-IN-23 (0.3-0.6 μM) increases the level of lipid peroxidation in SNB-75 central nervous system cancer cells in a concentration-dependent manner, with MDA levels increased by 2.5-fold and 3.5-fold at concentrations of 0.3 μM and 0.6 μM, respectively^[1].
GPX4-IN-23 (0.3-0.6 μM) dose-dependently depletes glutathione in SNB-75 CNS cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

399.49

C₂₄H₂₅N₅O

O=C(NC1=CC=CC=C1)NC2=CC=C(/C(C)=N/N=C/C3=CC=C(N(C)C)C=C3)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eldehna WM, et al. Biphenyl urea derivatives as novel GPX4 inhibitors: ferroptosis-mediated antiproliferative activity against CNS cancer cells. Bioorg Chem. Published online March 5, 2026.  [Content Brief]